Welcome to our dedicated page for Cyclerion Therapeutics news (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics stock.
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious and orphan diseases. Established in 2018 and headquartered in Cambridge, Massachusetts, Cyclerion harnesses the potential of soluble guanylate cyclase (sGC) pharmacology to create groundbreaking therapies for conditions with significant unmet medical needs.
The company's portfolio includes several promising product candidates:
- Olinciguat: An orally administered vascular sGC stimulator currently in Phase II studies aimed at treating sickle cell disease (SCD).
- Praliciguat: An orally administered systemic sGC stimulator in Phase II trials targeting diabetic nephropathy and heart failure with preserved ejection fraction.
- IW-6463: An orally administered, CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases.
In addition to these advanced candidates, Cyclerion is also working on discovering liver-targeted and lung-targeted sGC stimulators.
One of the latest developments for Cyclerion is its strategic partnership with Tisento Therapeutics, Inc. In July 2023, Cyclerion announced the closing of an asset purchase agreement with Tisento, which includes an $81 million Series A financing to support the development of Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat and other assets. Cyclerion received 10 percent equity ownership in Tisento, providing its shareholders with future value creation opportunities.
Cyclerion’s collaboration with Tisento marks a significant advancement, particularly for the brain-penetrant sGC stimulators zagociguat and CY3018. Phase 2a data from Cyclerion's studies demonstrated that zagociguat could significantly improve disease-associated biomarkers in patients with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), offering hope for better treatment options where none previously existed.
With a focus on delivering new therapeutic solutions, Cyclerion continues to explore collaborations, licenses, and other strategic options to enhance shareholder value while advancing its portfolio of innovative treatments.
Cyclerion Therapeutics announces the appointment of Dr. Errol De Souza to its board of directors, effective April 26, 2021. Dr. De Souza brings extensive experience in CNS drug development and has held leadership roles in various biotech firms. His expertise is expected to provide strategic guidance for Cyclerion's mission to restore cognitive function through innovative treatments. The company’s lead molecule, CY6463, is currently in clinical trials for cognitive impairment conditions, including Alzheimer’s Disease with vascular pathology and MELAS.
Cyclerion Therapeutics (Nasdaq: CYCN) announces that COO Cheryl Gault will present a corporate overview at B. Riley’s Neuroscience Investor Conference on April 29, 2021, at 1:00 p.m. ET. Attendees can also engage in one-on-one meetings with Cyclerion leaders at the event. The live webcast will be available on the Cyclerion website, along with an archived replay for 90 days. The company is focused on developing treatments to restore cognitive function, with its lead molecule, CY6463, currently in clinical development for Alzheimer's Disease with Vascular pathology and MELAS.
Cyclerion Therapeutics will host a webinar on April 27 at 8 a.m. EDT to discuss clinical updates for its CNS penetrant sGC stimulator, CY6463, focusing on its potential in treating Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy (MELAS). Key opinion leader Andreas Reif, M.D. will discuss the sGC pathway's role in Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion will also introduce a new candidate, CY3018, as part of their commitment to restore cognitive function.
TransMedics Group appointed Stephanie Lovell to its Board of Directors and the Nominating and Corporate Governance Committee, effective March 22, 2021. With over 30 years of experience in healthcare management and legal affairs, she currently serves as Executive Vice President and Chief Legal Officer for Blue Cross Blue Shield of Massachusetts. Lovell's expertise is expected to enhance TransMedics' strategy in the U.S. transplant market. The company aims to improve organ transplantation outcomes through innovative technologies that increase donor organ utilization.
Cyclerion Therapeutics (Nasdaq: CYCN) announced the resignation of Chief Medical Officer Christopher Wright, M.D., Ph.D., effective March 26, 2021. He will transition to a role on the Clinical Advisory Board, continuing to support the company. CEO Peter Hecht acknowledged Wright's contributions to clinical efforts. Cyclerion is focused on developing treatments for cognitive function, with its leading candidate, CY6463, showing promising results in clinical trials for Alzheimer's Disease with vascular pathology and MELAS.
Cyclerion Therapeutics (CYCN) reported its 2020 financial results and corporate updates, emphasizing the promising data from its lead asset, CY6463. The Phase 1 study confirmed favorable safety and blood-brain barrier penetration with improvements in cognitive biomarkers. The company announced upcoming Phase 2a trials for Alzheimer’s disease with vascular pathology and MELAS. Despite a net loss of approximately $77.8 million for 2020, Cyclerion expects reduced operating costs in 2021 from organizational changes, including a $10 million savings from exiting current facilities.
Cyclerion Therapeutics (Nasdaq: CYCN) announced the formation of clinical and scientific advisory boards to advance its therapeutic pipeline, particularly focusing on CY6463, a CNS-penetrant sGC stimulator targeting cognitive impairment. The new advisory boards consist of prominent experts in CNS diseases and therapeutic development, with a goal to optimize the company's development path. CY6463 is currently under clinical investigation for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS).
Cyclerion Therapeutics (Nasdaq: CYCN) announced its participation in two upcoming investor conferences. The company will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. ET, with a webcast available on their website. Additionally, an on-demand presentation will be available at the H.C. Wainwright BioConnect Conference on January 11, 2021, at 6:00 a.m. ET. Cyclerion focuses on innovative treatments for serious CNS diseases, notably their lead program, CY6463, aimed at conditions like MELAS and Alzheimer's with vascular pathology.
Cyclerion Therapeutics (Nasdaq: CYCN) announced key executive promotions effective January 1, 2021. Anjeza Gjino has been promoted to Chief Financial Officer, succeeding Bill Huyett, who will transition to a part-time Strategic Advisor role. Cheryl Gault is elevated to Chief Operating Officer. Amy Schulman is stepping down from the Board of Directors. Both Gjino and Gault have extensive backgrounds, with Gjino previously leading finance at Ironwood Pharmaceuticals and Gault having significant corporate strategy experience. These changes are expected to strengthen leadership and strategic direction at Cyclerion.
Cyclerion Therapeutics (Nasdaq: CYCN) announced positive results from its IW-6463 pharmacology study, showing significant benefits for age-related cognitive decline. The company plans to focus on its IW-6463 CNS program, with a projected 50% reduction in cash use for 2021 from Q3 2020 levels. Currently, cash reserves stand at approximately $71 million, expected to fund CNS priorities, including upcoming studies for MELAS and Alzheimer's disease. Despite impressive data, Cyclerion’s sickle cell program faced challenges, with inadequate activity results from the STRONG-SCD study.
FAQ
What is the current stock price of Cyclerion Therapeutics (CYCN)?
What is the market cap of Cyclerion Therapeutics (CYCN)?
What does Cyclerion Therapeutics, Inc. specialize in?
What are some of the key products in Cyclerion’s pipeline?
What recent partnership did Cyclerion enter?
What is zagociguat?
Where is Cyclerion Therapeutics headquartered?
What are the financial benefits of Cyclerion’s deal with Tisento?
Who are the major investors in Tisento’s Series A financing?
What is the focus of Cyclerion’s research and development?
What distinguishes Cyclerion’s approach to drug development?
How can investors and media contact Cyclerion?
